Resona Holdings, BrainPad, and Fujitsu sign basic agreement for collaboration to transform financial operations with data and AI and advance next-generation data utilization

Tokyo and Kawasaki, Japan, Mar 30, 2026 - (JCN Newswire via SeaPRwire.com) - Resona Holdings, Inc., BrainPad Inc., and Fujitsu Limited today announced the signing of a basic agreement for collaboration. The partnership aims to advance financial operations through the utilization of data and AI, and ...

MHI Innovative Combustion Dynamics Laboratory is Established at Kyoto University with the Aim of Developing and Socially Implementing World-Leading Technology

TOKYO, Mar 30, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and Kyoto University will operate an industry-academic laboratory, MHI Innovative Combustion Dynamics Laboratory, from April 1, with the aim of building world-class GTCC (gas turbine combined cycle) powe...

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced toda...

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc...